SAN

76.02

-0.3%↓

UCB

251.9

-3.12%↓

SHL.DE

39.06

-1.74%↓

ARGX

630.4

-0.85%↓

PHIA

24.69

-1.52%↓

SAN

76.02

-0.3%↓

UCB

251.9

-3.12%↓

SHL.DE

39.06

-1.74%↓

ARGX

630.4

-0.85%↓

PHIA

24.69

-1.52%↓

SAN

76.02

-0.3%↓

UCB

251.9

-3.12%↓

SHL.DE

39.06

-1.74%↓

ARGX

630.4

-0.85%↓

PHIA

24.69

-1.52%↓

SAN

76.02

-0.3%↓

UCB

251.9

-3.12%↓

SHL.DE

39.06

-1.74%↓

ARGX

630.4

-0.85%↓

PHIA

24.69

-1.52%↓

SAN

76.02

-0.3%↓

UCB

251.9

-3.12%↓

SHL.DE

39.06

-1.74%↓

ARGX

630.4

-0.85%↓

PHIA

24.69

-1.52%↓

Kodu・Aktsiate loetelu・Galapagos NV

Galapagos NV

Suletud

SektorTervishoid

27.88 -3.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.76

Max

28.84

Põhinäitajad
By Trading Economics
Sissetulek	985M 782M
Müük	830M 901M
Kasumimarginaal	86.864
Töötajad	704
EBITDA	938M 748M

Soovitused
By TipRanks
Soovitused	Müü
12 kuu keskmine prognoos	-19.15% downside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. mai 2026

Turustatistika
By TradingEconomics
Turukapital	108M 2B
Eelmine avamishind	31.21
Eelmine sulgemishind	27.88

Uudiste sentiment

By Acuity

65%

35%

293 / 351 Pingereas Healthcare

Galapagos NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. märts 2026, 20:38 UTC

Tulu

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10. märts 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10. märts 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10. märts 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10. märts 2026, 23:06 UTC

Tulu

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10. märts 2026, 22:51 UTC

Uudisväärsed sündmused

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10. märts 2026, 21:21 UTC

Tulu

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10. märts 2026, 21:15 UTC

Tulu

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10. märts 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10. märts 2026, 21:14 UTC

Tulu

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10. märts 2026, 21:13 UTC

Tulu

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10. märts 2026, 21:12 UTC

Tulu

Franco-Nevada 4Q Rev $597.3M >FNV

10. märts 2026, 21:12 UTC

Tulu

Franco-Nevada 4Q EPS $1.90

10. märts 2026, 20:57 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

10. märts 2026, 20:44 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:34 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

10. märts 2026, 20:34 UTC

Market Talk

Tulu

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10. märts 2026, 20:23 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10. märts 2026, 20:16 UTC

Tulu

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10. märts 2026, 20:14 UTC

Tulu

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10. märts 2026, 20:14 UTC

Tulu

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10. märts 2026, 20:13 UTC

Tulu

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10. märts 2026, 20:12 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Galapagos NV Prognoos

Hinnasiht

By TipRanks

-19.15% langus

12 kuu keskmine prognoos

Keskmine 22.75 EUR -19.15%

Kõrge 23.5 EUR

Madal 22 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Galapagos NV 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Galapagos NV aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

293 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.